Wei Lin - 01 Feb 2023 Form 4 Insider Report for Erasca, Inc. (ERAS)

Role: Chief Medical Officer
Signature: /s/ Ebun Garner, attorney-in-fact
Issuer symbol: ERAS
Transactions as of: 01 Feb 2023
Transactions value $: $7,169
Form type: 4
Filing time: 03 Feb 2023, 07:53:58 UTC
Previous filing: 03 Feb 2022
Next filing: 09 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ERAS	Common Stock	Other	$7.16K	+1.75K	+0.56%	$4.10	316K	01 Feb 2023	Direct	F1
transaction	ERAS	Common Stock	Other	$7.79	+2	+0%	$3.89	316K	01 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERAS	Stock Option (right to buy)	Award	$0	+560K		$0.00	560K	01 Feb 2023	Common Stock	560K	$4.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022.
F2	1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.